DexCom, a developer of continuous glucose monitoring systems, and certain executives were hit with a securities class action on Nov. 25 in California Southern District Court over alleged unauthorized ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Designed to provide real-time glucose readings for an ...
The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
DexCom and other defendants were hit with a securities class action on Nov. 10 in New York Southern District Court over alleged false statements about its G7 glucose monitoring device. The suit, ...
Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...
Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system app, leading the FDA to issue its most serious recall notice. A “software defect in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback